Amedeo Smart

Free Medical Literature Service


 

Amedeo

Liver Diseases

  Free Subscription

Articles published in
J Clin Oncol
    October 2025
  1. FRANSSEN S, Rousian M, Filipe WF, Buisman FE, et al
    Hepatic Arterial Infusion Pump Chemotherapy in Patients With Unresectable Intrahepatic Cholangiocarcinoma-PUMP-2 Trial.
    J Clin Oncol. 2025 Oct 13:JCO2500923. doi: 10.1200/JCO-25-00923.
    >> Share

    June 2025
  2. KAWAGUCHI Y, Hasegawa K, Kashiwabara K, Okamura Y, et al
    Surgery Versus Ablation for Hepatocellular Carcinoma: A Randomized Controlled Trial (SURF-RCT Trial) and a Nonrandomized Prospective Observational Trial (SURF-Cohort Trial).
    J Clin Oncol. 2025 Jun 24:JCO2402030. doi: 10.1200/JCO-24-02030.
    >> Share

    March 2025
  3. XI M, Fu Y, Zhang Y
    Reply to: Importance of Defining Recurrence in Hepatocellular Carcinoma: Local or Both Local and Other Intrahepatic Recurrences?
    J Clin Oncol. 2025 Mar 25:JCO2500327. doi: 10.1200/JCO-25-00327.
    >> Share

  4. KIBE Y
    Importance of Defining Recurrence in Hepatocellular Carcinoma: Local or Both Local and Other Intrahepatic Recurrences?
    J Clin Oncol. 2025 Mar 25:JCO2402861. doi: 10.1200/JCO-24-02861.
    >> Share

    February 2025
  5. FU Y, Zhang Y, Hu D, Zhou Z, et al
    Where Is the Future of Adjuvant Therapy for Hepatocellular Carcinoma?
    J Clin Oncol. 2025 Feb 25:JCO2402615. doi: 10.1200/JCO-24-02615.
    >> Share

  6. NEWMAN NB, Court CM, Parikh AA
    What Is the Optimal Locoregional Approach for Recurrent Hepatocellular Carcinoma?
    J Clin Oncol. 2025 Feb 11:JCO2402541. doi: 10.1200/JCO-24-02541.
    >> Share

    December 2024
  7. XI M, Yang Z, Hu L, Fu Y, et al
    Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Recurrent Small Hepatocellular Carcinoma: A Randomized, Open-Label, Controlled Trial.
    J Clin Oncol. 2024 Dec 18:JCO2401532. doi: 10.1200/JCO-24-01532.
    >> Share

  8. MAGYAR CTJ, O'Kane GM, Aceituno L, Li Z, et al
    Liver Transplantation for Hepatocellular Carcinoma: An Expanding Cornerstone of Care in the Era of Immunotherapy.
    J Clin Oncol. 2024 Dec 16:JCO2400857. doi: 10.1200/JCO.24.00857.
    >> Share

    October 2024

  9. Erratum: Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguan
    J Clin Oncol. 2024 Oct 10:JCO2402040. doi: 10.1200/JCO-24-02040.
    >> Share

    August 2024
  10. SHEN YC, Liu TH, Nicholas A, Soyama A, et al
    Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab.
    J Clin Oncol. 2024 Aug 28:JCO2400645. doi: 10.1200/JCO.24.00645.
    >> Share

    July 2024
  11. JAIN A, Lau NS
    Liver Transplantation in Colorectal Cancer With Unresectable Liver Metastases: Disease Biology Cannot Be Ignored.
    J Clin Oncol. 2024 Jul 8:JCO2400619. doi: 10.1200/JCO.24.00619.
    >> Share

    June 2024
  12. ETTRICH TJ, Modest DP, Sinn M, Striefler JK, et al
    Nanoliposomal Irinotecan With Fluorouracil and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Cholangiocarcinoma: A Phase II Study of the AIO Hepatobiliary-YMO Cancer Groups (NIFE-AIO-YMO HEP-0315).
    J Clin Oncol. 2024 Jun 6:JCO2301566. doi: 10.1200/JCO.23.01566.
    >> Share

  13. KAWAZOE A, Xu RH, Garcia-Alfonso P, Passhak M, et al
    Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study.
    J Clin Oncol. 2024 Jun 4:JCO2302736. doi: 10.1200/JCO.23.02736.
    >> Share

    May 2024
  14. SANGRO B, Galle PR, Kelley RK, Charoentum C, et al
    Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma.
    J Clin Oncol. 2024 May 28:JCO2301462. doi: 10.1200/JCO.23.01462.
    >> Share

  15. FICHTINGER RS, Aldrighetti LA, Abu Hilal M, Troisi RI, et al
    Laparoscopic Versus Open Hemihepatectomy: The ORANGE II PLUS Multicenter Randomized Controlled Trial.
    J Clin Oncol. 2024;42:1799-1809.
    >> Share

    April 2024
  16. CHAVEZ-VILLA M, Ruffolo LI, Line PD, Dueland S, et al
    Emerging Role of Liver Transplantation for Unresectable Colorectal Liver Metastases.
    J Clin Oncol. 2024;42:1098-1101.
    >> Share

    March 2024
  17. GORDAN JD, Kennedy EB, Abou-Alfa GK, Beal E, et al
    Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update.
    J Clin Oncol. 2024 Mar 19:JCO2302745. doi: 10.1200/JCO.23.02745.
    >> Share

    January 2024
  18. HUANG DQ, Hoang JK, Kamal R, Tsai PC, et al
    Antiviral Therapy Utilization and 10-Year Outcomes in Resected Hepatitis B Virus- and Hepatitis C Virus-Related Hepatocellular Carcinoma.
    J Clin Oncol. 2024 Jan 4:JCO2300757. doi: 10.1200/JCO.23.00757.
    >> Share

    November 2023
  19. WANG G, Zhuo N, Liu Z
    Nonalcoholic Fatty Liver Disease May Be an Independent, Modifiable Risk Factor for Young-Onset Digestive Tract Cancers.
    J Clin Oncol. 2023;41:5070.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016